Equity Profile

ORKA

Oruka Therapeutics, Inc.

Health CareBiotechnology$7.2B

Aug10Mon

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Oruka Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for various health conditions....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

While specific revenue estimates are not available, growth in revenue is crucial for assessing the company's market performance and future potential.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

ORKA Q2-2026 Earnings Preview

Context

Company Snapshot

Oruka Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for various health conditions. Operating in the health care sector, Oruka is part of a growing industry that emphasizes advancements in medical treatments and drug development.

Earnings Scorecard·Last 4Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+11.82%

Avg Stock Reaction

-2.31%

Last Quarter Recap

In Q1-2026, Oruka reported an EPS of -$0.48, beating expectations by 8.40%. However, the stock fell 2.27% the following day, indicating mixed investor sentiment.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic about Oruka's upcoming earnings report, especially given its history of beating EPS estimates. However, the lack of revenue guidance adds uncertainty.

Bull Case

If Oruka continues its trend of beating EPS estimates, it could signal strong operational performance and boost investor confidence.

Bear Case

On the other hand, if the company fails to deliver on expectations or provides weak guidance, it could lead to a significant drop in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026, and will it continue the trend of beating estimates?

Given Oruka's history of EPS surprises, this number will be critical in shaping investor sentiment.

Will there be any guidance on revenue growth or future product pipeline?

Lack of revenue guidance could lead to uncertainty, impacting the stock's performance post-earnings.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Oruka's ability to innovate and beat EPS estimates again this quarter, given its strong track record.

Supporting Evidence

Oruka has consistently beaten EPS estimates in the past four quarters.

Despite recent stock declines, the company's operational metrics suggest underlying strength.

The options market is pricing in high volatility, indicating that traders expect significant movement.

Key Risk

If the EPS comes in better than -$0.45, it could challenge the current cautious outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on whether Oruka can maintain its trend of EPS surprises and provide clarity on revenue growth.

Bull Confirmed If

An EPS of -$0.45 or better would confirm the bull case and suggest strong operational performance.

Bear Confirmed If

An EPS worse than -$0.50 would confirm the bear case, indicating potential challenges ahead.

Pre-Earnings Positioning

Options Market

Implied Move

±35.62%

Historical Avg

±2.5%

Pricing rich

The options market is pricing in a substantial move, suggesting that traders expect significant volatility around the earnings announcement.

Options are pricing ±35.6% while ORKA has averaged ±2.5% over the last 4 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

67.3%

Calls (600)P/C Ratio: 0.13Puts (6K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Oruka beats expectations, history suggests a potential average move of +2.49%, confirming positive investor sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await more clarity.

Miss

A miss could lead to a decline, with historical data suggesting an average move of -2.27% in response to disappointing results.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the product pipeline and upcoming clinical trials.
2Insights into cost management and operational efficiencies.
3Details on market conditions affecting revenue growth.
4Management's outlook on competitive positioning in the biotechnology sector.
5Responses to analyst questions regarding future guidance.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Tempus AI, Inc.

Company Snapshot

Oruka Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for various health conditions....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

While specific revenue estimates are not available, growth in revenue is crucial for assessing the company's market performance and future potential.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

ORKA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 4Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+11.82%

Avg Stock Reaction

-2.31%

Last Quarter Recap

In Q1-2026, Oruka reported an EPS of -$0.48, beating expectations by 8.40%. However, the stock fell 2.27% the following day, indicating mixed investor sentiment.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic about Oruka's upcoming earnings report, especially given its history of beating EPS estimates. However, the lack of revenue guidance adds uncertainty.

Bull Case

If Oruka continues its trend of beating EPS estimates, it could signal strong operational performance and boost investor confidence.

Bear Case

On the other hand, if the company fails to deliver on expectations or provides weak guidance, it could lead to a significant drop in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026, and will it continue the trend of beating estimates?

Given Oruka's history of EPS surprises, this number will be critical in shaping investor sentiment.

Will there be any guidance on revenue growth or future product pipeline?

Lack of revenue guidance could lead to uncertainty, impacting the stock's performance post-earnings.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Oruka's ability to innovate and beat EPS estimates again this quarter, given its strong track record.

Supporting Evidence

Oruka has consistently beaten EPS estimates in the past four quarters.

Despite recent stock declines, the company's operational metrics suggest underlying strength.

The options market is pricing in high volatility, indicating that traders expect significant movement.

Key Risk

If the EPS comes in better than -$0.45, it could challenge the current cautious outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on whether Oruka can maintain its trend of EPS surprises and provide clarity on revenue growth.

Bull Confirmed If

An EPS of -$0.45 or better would confirm the bull case and suggest strong operational performance.

Bear Confirmed If

An EPS worse than -$0.50 would confirm the bear case, indicating potential challenges ahead.

Pre-Earnings Positioning

Options Market

Implied Move

±35.62%

Historical Avg

±2.5%

Pricing rich

The options market is pricing in a substantial move, suggesting that traders expect significant volatility around the earnings announcement.

Options are pricing ±35.6% while ORKA has averaged ±2.5% over the last 4 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

67.3%

Calls (600)P/C Ratio: 0.13Puts (6K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Oruka beats expectations, history suggests a potential average move of +2.49%, confirming positive investor sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await more clarity.

Miss

A miss could lead to a decline, with historical data suggesting an average move of -2.27% in response to disappointing results.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the product pipeline and upcoming clinical trials.
2Insights into cost management and operational efficiencies.
3Details on market conditions affecting revenue growth.
4Management's outlook on competitive positioning in the biotechnology sector.
5Responses to analyst questions regarding future guidance.